Renovacor, Inc., (RCOR): Price and Financial Metrics


Renovacor, Inc., (RCOR): $1.96

-0.08 (-3.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RCOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RCOR Stock Price Chart Interactive Chart >

Price chart for RCOR

RCOR Price/Volume Stats

Current price $1.96 52-week high $10.74
Prev. close $2.04 52-week low $1.94
Day low $1.96 Volume 4,800
Day high $1.97 Avg. volume 16,489
50-day MA $3.57 Dividend yield N/A
200-day MA $6.96 Market Cap 33.84M

Renovacor, Inc., (RCOR) Company Bio


Renovacor, Inc., an early-stage biotechnology company, engages in developing a pipeline of adeno-associated virus (AAV) based gene therapies for Bcl2-associated athanogene 3 (BAG3) associated diseases. Its lead program is recombinant AAV-based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the BAG3 gene; and REN-001, an AAV9-based gene therapy to treat BAG3-associated DCM. The company was incorporated in 2013 and is based in Greenwich, Connecticut.


RCOR Latest News Stream


Event/Time News Detail
Loading, please wait...

RCOR Latest Social Stream


Loading social stream, please wait...

View Full RCOR Social Stream

Latest RCOR News From Around the Web

Below are the latest news stories about Renovacor Inc that investors may wish to consider to help them evaluate RCOR as an investment opportunity.

Renovacor to Participate in a Panel Presentation at the 11th Annual LifeSci Partners Corporate Access Event

PHILADELPHIA, January 03, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced that Magdalene Cook, M.D., President and Chief Executive Officer of Renovacor, will participate in a panel presentation at the 11th Annual LifeSci Partners Corporate Access Event.

Yahoo | January 3, 2022

Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...

Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp.

Yahoo | December 23, 2021

Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update

PHILADELPHIA, November 15, 2021--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced financial results for the third quarter of 2021 and provided a corporate update.

Yahoo | November 15, 2021

Renovacor Announces the Appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations

PHILADELPHIA, October 04, 2021--Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations.

Yahoo | October 4, 2021

Renovacor to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

PHILADELPHIA, September 28, 2021--Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced that Magdalene Cook, M.D., Chief Executive Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetics Medicines Conference on Tuesday, October 5, 2021, at 11:30 a.m. EDT.

Yahoo | September 28, 2021

Read More 'RCOR' Stories Here

RCOR Price Returns

1-mo -47.73%
3-mo -59.34%
6-mo -77.73%
1-year -80.40%
3-year N/A
5-year N/A
YTD -74.55%
2021 -24.51%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3932 seconds.